BIOMAT Database Logo BIOMAT Database Logo

Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya. 2012

Christine J McGrath, and Julia Njoroge, and Grace C John-Stewart, and Pamela K Kohler, and Sarah F Benki-Nugent, and Joan W Thiga, and Anthony Etyang, and Michael H Chung
Department of Global Health, University of Washington, Seattle, WA 98104-2499, USA. mcgrathc@u.washington.edu

The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described. We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4T-based and 269 (15 %) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n=236) among d4T users and 6.9 (n=7) among ZDV users (P=0.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P=0.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.

UI MeSH Term Description Entries
D007630 Kenya A republic in eastern Africa, south of ETHIOPIA, west of SOMALIA with TANZANIA to its south, and coastline on the Indian Ocean. Its capital is Nairobi. Republic of Kenya
D008297 Male Males
D010523 Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves. Peripheral Nerve Diseases,Peripheral Neuropathies,PNS (Peripheral Nervous System) Diseases,PNS Diseases,Peripheral Nervous System Disease,Peripheral Nervous System Disorders,Nerve Disease, Peripheral,Nerve Diseases, Peripheral,Neuropathy, Peripheral,PNS Disease,Peripheral Nerve Disease,Peripheral Neuropathy
D011336 Probability The study of chance processes or the relative frequency characterizing a chance process. Probabilities
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Christine J McGrath, and Julia Njoroge, and Grace C John-Stewart, and Pamela K Kohler, and Sarah F Benki-Nugent, and Joan W Thiga, and Anthony Etyang, and Michael H Chung
Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: effect of stavudine exposure and antiretroviral experience.
January 2002, Advances in therapy,
Christine J McGrath, and Julia Njoroge, and Grace C John-Stewart, and Pamela K Kohler, and Sarah F Benki-Nugent, and Joan W Thiga, and Anthony Etyang, and Michael H Chung
Peripheral neuropathy during stavudine-didanosine antiretroviral therapy.
April 2001, HIV medicine,
Christine J McGrath, and Julia Njoroge, and Grace C John-Stewart, and Pamela K Kohler, and Sarah F Benki-Nugent, and Joan W Thiga, and Anthony Etyang, and Michael H Chung
Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens.
January 2015, Journal of the International Association of Providers of AIDS Care,
Christine J McGrath, and Julia Njoroge, and Grace C John-Stewart, and Pamela K Kohler, and Sarah F Benki-Nugent, and Joan W Thiga, and Anthony Etyang, and Michael H Chung
Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals.
March 2000, AIDS (London, England),
Christine J McGrath, and Julia Njoroge, and Grace C John-Stewart, and Pamela K Kohler, and Sarah F Benki-Nugent, and Joan W Thiga, and Anthony Etyang, and Michael H Chung
Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya.
September 2010, The American journal of tropical medicine and hygiene,
Christine J McGrath, and Julia Njoroge, and Grace C John-Stewart, and Pamela K Kohler, and Sarah F Benki-Nugent, and Joan W Thiga, and Anthony Etyang, and Michael H Chung
Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens.
May 2004, Journal of acquired immune deficiency syndromes (1999),
Christine J McGrath, and Julia Njoroge, and Grace C John-Stewart, and Pamela K Kohler, and Sarah F Benki-Nugent, and Joan W Thiga, and Anthony Etyang, and Michael H Chung
Time Preferences Predict Mortality among HIV-Infected Adults Receiving Antiretroviral Therapy in Kenya.
January 2015, PloS one,
Christine J McGrath, and Julia Njoroge, and Grace C John-Stewart, and Pamela K Kohler, and Sarah F Benki-Nugent, and Joan W Thiga, and Anthony Etyang, and Michael H Chung
Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
May 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Christine J McGrath, and Julia Njoroge, and Grace C John-Stewart, and Pamela K Kohler, and Sarah F Benki-Nugent, and Joan W Thiga, and Anthony Etyang, and Michael H Chung
Emergence of zidovudine resistance in HIV-infected patients receiving stavudine.
March 2000, Journal of acquired immune deficiency syndromes (1999),
Christine J McGrath, and Julia Njoroge, and Grace C John-Stewart, and Pamela K Kohler, and Sarah F Benki-Nugent, and Joan W Thiga, and Anthony Etyang, and Michael H Chung
Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
May 2008, HIV medicine,
Copied contents to your clipboard!